Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price traded up 4.5% on Friday . The company traded as high as $55.69 and last traded at $54.77. 10,026,739 shares were traded during trading, a decline of 49% from the average session volume of 19,617,847 shares. The stock had previously closed at $52.40.
Analyst Ratings Changes
Several brokerages have weighed in on HIMS. UBS Group reaffirmed a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Morgan Stanley cut their target price on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 29th. Leerink Partners upped their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Truist Financial dropped their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Finally, Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $37.67.
Check Out Our Latest Research Report on HIMS
Hims & Hers Health Trading Up 8.3%
The business's fifty day moving average price is $39.85 and its 200 day moving average price is $36.01. The company has a market capitalization of $12.70 billion, a P/E ratio of 128.96 and a beta of 1.84.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same period in the previous year, the firm posted $0.05 earnings per share. The company's revenue was up 110.7% on a year-over-year basis. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.
Insider Activity
In other news, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $52.98, for a total value of $613,561.38. Following the sale, the chief financial officer now owns 39,153 shares of the company's stock, valued at $2,074,325.94. The trade was a 22.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Irene Becklund sold 2,203 shares of the business's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the sale, the insider now directly owns 8,007 shares in the company, valued at approximately $230,441.46. This represents a 21.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold 621,518 shares of company stock worth $25,415,264 over the last quarter. 13.71% of the stock is currently owned by company insiders.
Institutional Trading of Hims & Hers Health
A number of institutional investors have recently made changes to their positions in the business. Crewe Advisors LLC bought a new stake in Hims & Hers Health during the fourth quarter worth $28,000. Blume Capital Management Inc. raised its position in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health during the first quarter worth $30,000. Smartleaf Asset Management LLC raised its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new stake in Hims & Hers Health during the fourth quarter worth $38,000. Institutional investors own 63.52% of the company's stock.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
See Also
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
